Ketamine and Esketamine in Residential Mental Health for Treatment-Resistant Depression

For a person whose depression has not responded to two or more adequate trials of standard antidepressants, the treatment options that remain are meaningfully different from the standard first-line playbook. Ketamine and its FDA-approved cousin esketamine (Spravato) have moved from experimental to mainstream over the past decade, and integrating them into a residential mental health stay is now one of the most effective ways to shorten the arc from acute suicidal depression to stable remission. At Bodhi Mental Health, we build ketamine and esketamine protocols into residential care for patients whose depression has resisted the standard sequence.

This article covers how ketamine and esketamine differ, the evidence supporting their use in treatment-resistant depression, why the residential setting is often the right place to initiate treatment, how we sequence infusions or intranasal dosing with psychotherapy, and the safety monitoring that has to happen alongside every dose.

How Ketamine and Esketamine Differ

Ketamine is a racemic anesthetic that has been in medical use for decades and is administered off-label for depression, typically by intravenous infusion at sub-anesthetic doses. Esketamine is the S-enantiomer of ketamine, formulated as an intranasal spray and FDA-approved specifically for treatment-resistant depression and for major depressive disorder with acute suicidal ideation. The FDA approved Spravato in 2019 under a Risk Evaluation and Mitigation Strategy that requires administration in a certified healthcare setting.

Both act primarily on NMDA glutamate receptors, a different mechanism than the monoamine reuptake pathway of standard antidepressants. This is why they often work in patients who have failed multiple SSRIs and SNRIs, and why response can occur within hours to days rather than the four to six weeks typical of standard antidepressants. The National Institute of Mental Health summarizes the current evidence base for both agents.

Why the Residential Setting Is Often the Right Place to Start

Initiating ketamine or esketamine treatment requires close clinical monitoring for the first few doses because dissociative side effects and transient blood pressure elevations are common in the two hours immediately after administration. In an outpatient model, patients drive to a clinic, receive the dose, are observed for two hours, and are then discharged home, often to arrange their own follow-up. In a residential setting, the same patient stays on-site with twenty-four-hour clinical support, which matters most for patients who are severely depressed or actively suicidal.

The residential setting also makes it possible to integrate the medication with intensive daily therapy in a way that outpatient dosing cannot. A patient can receive an esketamine dose in the morning and process the emerging cognitive shifts in individual therapy that afternoon, and again in group therapy the next day. Read our companion article on TMS therapy in residential mental health treatment-resistant depression for how we sequence other neuromodulation options.

The Evidence Base for Treatment-Resistant Depression

The pivotal esketamine trials showed statistically significant improvement in depression rating scales compared with placebo when added to a newly initiated oral antidepressant, and durability studies have shown that maintenance dosing extends remission. Racemic IV ketamine has a larger clinical experience base though a smaller regulatory footprint, and the two are often used interchangeably in clinical practice depending on formulary, insurance coverage, and patient preference.

For patients with major depressive disorder and acute suicidal ideation, the specific indication esketamine holds, the evidence is particularly strong that the medication can reduce suicidal ideation within twenty-four hours in a way no other antidepressant can match. The 988 Suicide and Crisis Lifeline is always the first resource for anyone in acute crisis; residential ketamine or esketamine care is one of the higher-acuity treatment options once a patient is medically stable. See our overview on when severe symptoms warrant residential treatment.

How We Sequence Ketamine or Esketamine with Psychotherapy

The typical Spravato induction is twice-weekly dosing for four weeks, then weekly for four weeks, then every one to two weeks for maintenance. IV ketamine protocols vary but often use a series of six infusions over two to three weeks during acute treatment. In our residential program, the medication schedule is timed to align with a structured therapy calendar that includes daily individual sessions, DBT skills groups, and specific integration sessions to make use of the neuroplasticity window that follows dosing.

Ketamine and esketamine appear to open a period of increased neuroplasticity in the hours to days after a dose, during which the brain may be more responsive to therapy. We time cognitive and processing work to that window rather than to arbitrary calendar slots. See our related post on GeneSight vs Genomind for treatment-resistant depression for how pharmacogenomic testing can inform which oral antidepressant we pair with esketamine.

Safety Monitoring and Contraindications

Blood pressure is measured before dosing and at forty and ninety minutes after. Dissociation is expected in the first two hours and typically resolves without intervention. Nausea, dizziness, and sedation are also common. Patients cannot drive for the remainder of the day after any dose, which is another argument for the residential setting during induction. Contraindications include uncontrolled hypertension, active psychosis, and a history of aneurysmal vascular disease.

Ongoing monitoring throughout treatment includes standardized depression and suicidality scales, side effect tracking, and coordination with the outpatient psychiatrist who will manage maintenance dosing after discharge. Our related post on DBT in residential mental health treatment covers one of the therapy modalities we most often pair with ketamine or esketamine dosing.

Getting Started at Bodhi Mental Health

If depression has not responded to two or more antidepressants at adequate dose and duration, or if suicidal ideation is present, a residential mental health stay with integrated ketamine or esketamine can be a meaningful option worth discussing. Our admissions team can complete a clinical assessment by phone and verify PPO insurance benefits typically within an hour.

Call Bodhi Mental Health at 877-883-0780 to speak with an admissions counselor today, or visit our admissions page to begin the process online.